vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and KalVista Pharmaceuticals, Inc. (KALV). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $13.7M, roughly 1.4× KalVista Pharmaceuticals, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -361.4%, a 360.6% gap on every dollar of revenue.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel oral serine protease inhibitor therapies. Its core pipeline addresses unmet medical needs for rare and inflammatory diseases including hereditary angioedema and diabetic macular edema, with primary target markets in North America and Europe.
CTMX vs KALV — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $13.7M |
| Net Profit | $-154.0K | $-49.5M |
| Gross Margin | — | 91.0% |
| Operating Margin | -6.9% | -336.3% |
| Net Margin | -0.8% | -361.4% |
| Revenue YoY | -25.7% | — |
| Net Profit YoY | 97.6% | -17.1% |
| EPS (diluted) | — | $-0.92 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $13.7M | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $50.9M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $33.4M | $0 | ||
| Q2 24 | $25.1M | — | ||
| Q1 24 | $41.5M | — | ||
| Q4 23 | $26.6M | — |
| Q3 25 | — | $-49.5M | ||
| Q2 25 | $-154.0K | — | ||
| Q1 25 | $23.5M | — | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $-40.4M | ||
| Q2 24 | $-6.5M | — | ||
| Q1 24 | $13.8M | — | ||
| Q4 23 | $837.0K | — |
| Q3 25 | — | 91.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | — | -336.3% | ||
| Q2 25 | -6.9% | — | ||
| Q1 25 | 44.4% | — | ||
| Q4 24 | 46.4% | — | ||
| Q3 24 | 12.3% | — | ||
| Q2 24 | -33.7% | — | ||
| Q1 24 | 28.1% | — | ||
| Q4 23 | -2.3% | — |
| Q3 25 | — | -361.4% | ||
| Q2 25 | -0.8% | — | ||
| Q1 25 | 46.2% | — | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | — | ||
| Q2 24 | -26.0% | — | ||
| Q1 24 | 33.3% | — | ||
| Q4 23 | 3.1% | — |
| Q3 25 | — | $-0.92 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.87 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $243.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $17.0M |
| Total Assets | $175.1M | $339.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $243.5M | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | $31.8M | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — | ||
| Q4 23 | $17.2M | — |
| Q3 25 | — | $17.0M | ||
| Q2 25 | $119.9M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $-456.0K | — | ||
| Q3 24 | $-23.5M | $172.8M | ||
| Q2 24 | $-31.2M | — | ||
| Q1 24 | $-31.7M | — | ||
| Q4 23 | $-47.4M | — |
| Q3 25 | — | $339.9M | ||
| Q2 25 | $175.1M | — | ||
| Q1 25 | $98.5M | — | ||
| Q4 24 | $120.5M | — | ||
| Q3 24 | $139.0M | $200.2M | ||
| Q2 24 | $159.2M | — | ||
| Q1 24 | $184.7M | — | ||
| Q4 23 | $201.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | — |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.0M | — | ||
| Q4 24 | $-19.9M | — | ||
| Q3 24 | $-20.7M | $-40.2M | ||
| Q2 24 | $-19.5M | — | ||
| Q1 24 | $-26.0M | — | ||
| Q4 23 | $-22.0M | — |
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | $-40.2M | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — | ||
| Q4 23 | $-22.2M | — |
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — | ||
| Q4 23 | -83.5% | — |
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — | ||
| Q4 23 | 1.0% | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — | ||
| Q4 23 | -26.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
KALV
Segment breakdown not available.
